



THERMOGENESIS CORP. TO ANNOUNCE FOURTH QUARTER AND YEAR END RESULTS ON SEPTEMBER 9

COMPANY PROVIDES PRESENTATION DETAILS FOR RODMAN & RENSHAW CONFERENCE TO BE WEBCAST

RANCHO CORDOVA, Calif. – (September 8, 2009) ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report final financial results for the fourth quarter and full fiscal year 2009 ended June 30, 2009, on Wednesday, September 9, 2009.

Company's Conference Call and Webcast

Management will host a conference call Wednesday, September 9, 2009 at 2:00 PM Pacific (5:00 PM Eastern) to review the fourth quarter and fiscal year end 2009 results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. J. Melville Engle, Chief Executive Officer and Mr. Matthew Plavan, Executive Vice President, Chief Operating Officer and Chief Financial Officer will host the call to discuss the fourth quarter and year end results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

To listen to the audio webcast of the call during or after the event, please visit:

<http://www.thermogenesis.com/investors-webcasts-and-calls.aspx>.

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

Rodman & Renshaw Conference Details

The Company will be participating in the Rodman & Renshaw Annual Global Investment Conference on Friday, September 11, 2009.

The presentation by J. Melville Engle, Chief Executive Officer, will begin at 9:35 a.m., Eastern Daylight Time (6:35 a.m., Pacific Daylight Time).

The presentation will be available through the conference website at <http://www.wsw.com/webcast/rrshq15/kool>, and the Company's website at <http://www.thermogenesis.com/investors-webcasts-and-calls.aspx>

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

- **The BioArchive[®] System**, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- **AXP[®] AutoXpress[™] Platform (AXP)**, a proprietary family of automated devices that includes the AXP and the MXP[™] MarrowXpress[™] and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China, Russia/CIS and Japan, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow.
- **The Res-Q[™] 60 BMC (Res-Q)**, a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
- **The CryoSeal[®] FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009 and fiscal 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: <http://www.thermogenesis.com>
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com